SPI

1 stories about SPI
David Harel CytoReason

CytoReason enters Japanese market with SPI partnership

30.09.21|James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
ProfilesEngineServlet?at=39&mi=10&pt=18&dpi=1243103233&pai=cTech&dpn=4409&mt=1